Showing 31-40 of 5314 results for "".
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iibiic-melanoma/36324/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma
https://practicaldermatology.com/programs/cme/clinical-data-prompting-guideline-updates-for-subcutaneous-icis-in-melanoma/36329/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
https://practicaldermatology.com/programs/cme/clinical-implications-of-neoadjuvant-therapy-guideline-updates-in-resectable-melanoma/36323/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
https://practicaldermatology.com/programs/cme/data-driving-preferred-guideline-recommendations-in-first-line-therapy-for-metastatic-melanoma/36327/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
https://practicaldermatology.com/programs/cme/implementing-guideline-concordant-care-for-a-patient-with-newly-diagnosed-stage-iii-melanoma/36326/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
https://practicaldermatology.com/programs/cme/insights-from-global-key-opinion-leaders-on-regional-regulatory-and-guideline-nuances-to-optimize-melanoma-management/36331/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
https://practicaldermatology.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-melanoma/33212/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Tri-State Analysis of the Distribution of Southeastern Dermatologists and Dermatology Residency Graduates Among Rural and Urban Areas
https://practicaldermatology.com/issues/november-2024/tri-state-analysis-distribution-southeastern-dermatologists-and-dermatology-residency-graduates-among-rural-and-urban-areas/29799/The nation faces a shortage of dermatologists, and this issue is most prevalent in rural areas. The objective of this study is to analyze the distribution of dermatologists and graduates of dermatology residency programs across the southeastern region and the factors that influence this distributionFighting for Coverage: Combatting Private Insurance to Get Patients the Drugs They Need
https://practicaldermatology.com/issues/july-2025/fighting-for-coverage/36503/Aside from decreasing reimbursement rates, obtaining prior authorization from private insurance for medications that our patients desperately need to improve their lives, improve their skin conditions, and improve their wellbeing is probably the greatest challenge that dermatologists face today.